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ABSTRACT
TNF- is a proinflammatory cytokine, dramatically ele-
vated during pathogenic infection and often responsible
for inflammation-induced disease pathology. SOCS pro-
teins are inhibitors of cytokine signaling and regulators
of inflammation. In this study, we found that both SOCS1
and SOCS3 were transiently induced by TNF- and neg-
atively regulate its NF-B-mediated signal transduction.
We discovered that PBMCs from HCV-infected patients
have elevated endogenous SOCS3 expression but less
TNF--mediated IB degradation and proinflammatory
cytokine production than healthy controls. HCV protein
expression in Huh7 hepatocytes also induced SOCS3
and directly inhibited TNF--mediated IL-8 production.
Furthermore, we found that SOCS3 associates with
TRAF2 and inhibits TRAF2-mediated NF-B promoter
activity, suggesting a mechanism by which SOCS3 in-
hibits TNF--mediated signaling. These results demon-
strate a role for SOCS3 in regulating proinflammatory
TNF- signal transduction and reveal a novel immune-
modulatory mechanism by which HCV suppresses in-
flammatory responses in primary immune cells and
hepatocytes, perhaps explaining mild pathology often
associated with acute HCV infection. J. Leukoc. Biol.
96: 255–263; 2014.
Introduction
TNF- is an important proinflammatory cytokine produced in
response to infection. Excess levels of TNF- are implicated in
a range of inflammatory conditions, including rheumatoid ar-
thritis, septic shock, inflammatory bowel disease, and viral hep-
atitis [1–3]. A key role for TNF- in the pathology associated
with chronic inflammation is emphasized by successful target-
ing of arthritis and inflammatory bowel disease with therapeu-
tic anti-TNF- [4]. The effects of TNF- are mediated through
TNFR1 and TNFR2, leading to proliferation, inflammation,
and apoptosis [5]. Upon receptor binding, TNF- signals
through a variety of cytosolic proteins, including TRADD [6]
and TRAF2 [7], leading to IB degradation and the subse-
quent release and nuclear translocation of NF-B. Binding of
NF-B to gene promoters initiates transcription of numerous
proinflammatory cytokines, including IL-6, IL-8, TNF-, and
CXCL-10 [8, 9]. Interestingly, CXCL-10 can also be induced by
TNF- via the MAPK pathway [10]. TNF- signaling is known
to be regulated by the deubiquitinating enzyme, A20, which
removes Lys-63-linked, nondegradative ubiquitin chains from
the receptor-interacting protein and promotes its Lys-48-linked
polyubiquitination, thus targeting it for proteasomal degrada-
tion [11]. However, unchecked TNF- signaling results in
chronic inflammation, cell death, and tumorigenesis, as dem-
onstrated in A20-deficient mice [12]. Whereas ubiquitination
is a critical regulatory mechanism of the TNF- pathway, it is
likely that this essential proinflammatory cytokine pathway is
controlled by other unknown mechanisms to ensure an appro-
priate response to infection.
SOCS, a family of eight inhibitory intracellular proteins (CIS
and SOCS1–7), are rapidly induced in response to numerous
cytokines and microbial products, including IFN-, growth hor-
mone, IL-2, fMLP, and LPS [13–15]. SOCS act in a negative-
feedback loop to regulate inflammatory responses and were
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discovered initially as inhibitors of the JAK/STAT pathway but
are increasingly believed to regulate other pathways [16, 17].
Many patients (50–85%) fail to clear HCV, resulting in
chronic infection [18]. Acute HCV disease progression is me-
diated by the expression of proinflammatory cytokines, such as
IL-8, IL-6, and TNF-; however, significant pathology is un-
common in these patients, meaning that infection often re-
mains undetected for many years [19, 20]. The mechanism by
which pathology is limited during HCV infection is unknown.
A role for SOCS proteins during HCV infection has been sug-
gested [21–24], which led us to investigate whether HCV-in-
duced SOCS could regulate proinflammatory cytokine induc-
tion, thus contributing to the mild pathology associated with
HCV infection [25].
In this study, we demonstrate that SOCS1 and SOCS3 are
induced by TNF- and inhibit its NF-B signal transduction.
We also found that SOCS3 levels are elevated in PBMCs from
HCV-infected patients, which may be responsible for the ob-
served reduction in TNF--mediated IB degradation and pro-
inflammatory cytokine production. Furthermore, HCV in-
duced SOCS3 in Huh7 hepatocytes, which directly inhibited
TNF--induced, proinflammatory IL-8 expression, possibly by
blocking the NF-B pathway through direct association with
TRAF2. These findings suggest a novel mechanism by which
HCV suppresses inflammatory responses, possibly explaining
the mild pathology often associated with acute HCV infection.
MATERIALS AND METHODS
Patient samples
Twenty-one patients attending the HCV out-patient clinic at St. Vincent’s
University Hospital (Dublin, Ireland) were recruited for this study. All were
infected with genotype 1 HCV, and no one had undergone IFN-/ribavirin
therapy. Detailed clinical information is provided in Supplemental Tables
1–3. Written, informed consent was obtained from each patient, and the
study received ethical approval from the local Research and Ethics Com-
mittee at St. Vincent’s University Hospital, in accordance with the guide-
lines of the 1975 Declaration of Helsinki. All patients tested positive for
antibodies to HCV, using a third-generation enzyme immunoassay (Abbott
Diagnostics, Lake Forest, IL, USA) and a third-generation recombinant im-
munoblot assay-3 (Chiron, Emeryville, CA, USA). Control blood was ob-
tained from healthy volunteers.
PBMC isolation
Whole blood (30 ml) was obtained from each patient and control.
PBMCs were isolated by density gradient centrifugation at 1580 g for 5
min over Ficoll (Amersham, Amersham, UK). The cells were then
washed twice at 290 g for 5 min with RPMI medium before being resus-
pended in 1 ml and counted.
Cell culture
MEFs [a kind gift from Professor Aki Yoshimura (Keio University, Japan)],
Huh7 cells [a kind gift from Professor Ralf Bartenschlarger (University of
Heidelberg, Germany)], and 293T embryonic kidney cells (Invitrogen, San
Diego, CA, USA) were grown in DMEM and PBMCs in RPMI, supple-
mented with 10% FCS, 2 mM L-glutamine, 250 U/ml penicillin, and 250
g/ml streptomycin and cultured at 37°C in 5% CO2 and 95% humidity.
Cells were treated with 20 ng/ml TNF- (PeproTech, Rocky Hill, NJ, USA),
and SOCS1/ MEFs were retrovirally infected with SOCS1 pMX-IRES-
EGFP (termed SOCS1) and SOCS3/ MEFs with SOCS3 pMX-IRES-
EGFP (termed SOCS3), as described previously [26].
Transfection
Huh7 cells, expressing a T7 polymerase, were transfected with 0.5 g
pBRTM/HCV1-3011 DNA construct (containing the structural and non-
structural proteins of HCV genotype 1b) [27] and a control EV (pBR322)
and 0.5 g shRNA SOCS3 and scrambled control shRNA for 24 h using
Lipofectamine 2000 (Invitrogen), according to the manufacturer’s instruc-
tions. Cells were then stimulated for 18 h with 20 ng/ml TNF- (Pepro-
Tech), and the supernatant was stored at 20°C until analysis. Levels of
IL-8 and CXCL-10 were measured in the cell culture supernatants by
ELISA, as directed by the manufacturer (BioLegend, San Diego, CA, USA).
Transfection of 293T cells was carried out for 48 h with SOCS1, -2, or -3
constructs (3 g) using Lipofectamine 2000.
RT-PCR analysis
Total RNA was isolated from cells using Trizol reagent (Invitrogen), follow-
ing the manufacturer’s protocol. RNA yields and quality were assessed us-
ing a NanoDrop ND-1000 spectrophotometer (Thermo Scientific, Waltham,
MA, USA). RT-PCR was performed with 1 g total cell RNA following the
OneStep kit protocol (Qiagen, Hilden, Germany). Reactions were incu-
bated for 30 min at 50°C, 95°C for 15 min, and subjected to 35 denaturing
(94°C), annealing (58°C), and extending (72°C) cycles for 30 s, followed
by a final extension step of 72°C for 10 min. All primers for real-time RT-
PCR were designed using Primer3 software (http://primer3.sourceforge.
net/) and commercially synthesized (Invitrogen). PCR amplification was
performed using primer pairs (see Supplemental Figure 1). The PCR prod-
ucts were separated on a 2% agarose gel and visualized by ethidium bro-
mide staining.
For real-time qRT-PCR, 1 g total RNA from each sample was reverse-
transcribed into cDNA with oligo-dT primers using an Omniscript RT Kit,
according to the manufacturer’s instructions (Qiagen). A total of 40 ng
cDNA was used for each real-time RT-PCR reaction. PCR amplification was
performed using specific primer pairs (see Supplemental Figure 2). Each
reaction was carried out in duplicate. Real-time RT-PCR was performed us-
ing a MX3000P qPCR system (Stratagene, La Jolla, CA, USA), with the fol-
lowing cycling parameters: 95°C for 30 s, 60°C for 1 min, and 72°C for 30
s, followed by amplicon dissociation. All gene amplifications for human
samples were normalized to ribosomal protein 15. GAPDH was used as the
endogenous reference gene for all murine genes analyzed. Data analysis
was carried out using the 2 comparative threshold method [28].
Immunoblot analysis
Cells were harvested in radioimmunoprecipitation assay lysis buffer, supple-
mented with aprotinin (5 g/ml), leupeptin (5 g/ml), PMSF (1 mM),
and Na3VO4 (1 mM) on ice for 15 min. Extracts were pelleted at 12,000 g
at 4°C for 15 min. Total lysates were resolved by PAGE, and protein was
transferred from the gel to a polyvinylidene difluoride membrane using
semidry transfer. Primary antibodies were diluted 1:1000 in PBS with 5%
milk and incubated at 4°C overnight. Primary antibodies SOCS1 (Invitro-
gen), SOCS2 (New England Biolabs, Ipswich, MA, USA), SOCS3 (Abcam,
Cambridge, UK), IB [a kind gift from Professor Ron Hay (University of
Dundee, Scotland, UK)], NS2 [a kind gift from Professor Charles Rice
(The Rockefeller University, New York, NY, USA)], -actin (Sigma, St.
Louis, MO, USA), GAPDH (Sigma), and -tubulin (Sigma) and infrared
dye-labeled (Li-Cor, Lincoln, NE, USA) or HRP-labeled (New England Bio-
labs) secondary antibodies—goat anti-rabbit and goat anti-mouse—were
used for detection. Proteins were analyzed on an Odyssey Infrared Imaging
system using near-infrared fluorescence detection. Immunoblots analyzed
using the Odyssey system were quantified using Li-Cor software, and immu-
noblots analyzed using photographic film were quantified using ImageJ
software (U.S. National Institutes of Health, Bethesda, MD, USA).
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Flow cytometry
MEFs were surface-labeled with PE-conjugated TNFR or isotype control an-
tibody (BD Biosciences, San Jose, CA, USA). Cells were fixed with 4% para-
formaldehyde for 30 min on ice, washed 2 in PBS, and acquired using a
Dako Cyan flow cytometer. Data were analyzed using FlowJo software (Tree
Star, Ashland, OR, USA).
Immunoprecipitation
HEK293T cells were transfected with 1 g EV or myc-SOCS3 and Flag-
TRAF2 for 24 h. Thereafter, cells were lysed in 600 l lysis buffer (50 mM
HEPES, pH 7.5, 150 mM NaCl, 2 mM EDTA, pH 8, 1% Nonidet P-40, and
0.5% sodium deoxycholate, supplemented with 1 mM PMSF, 1 mM dithio-
threitol, and 1 mM NaVO3) and left on ice for 20 min. Extracts were pel-
leted at 12,000 g at 4°C for 15 min. Next, cell lysates were incubated with
1 g anti-SOCS3 antibody (Abcam), precoupled to 30 l A/G Plus Aga-
rose beads (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 2 h at
4°C with gentle shaking. The immune complexes were precipitated,
washed, and subjected to immunoblotting analysis using an anti-myc
and anti-Flag antibodies.
Reporter gene assays
HEK293T cells were plated into 96-well plates at a density of 5  104 cells/
well. After 24 h, cells were cotransfected with vectors encoding the firefly
luciferase reporter gene under the control of five NF-B sites (80 ng/well)
and a control Renilla luciferase construct (40 ng/well) and cotransfected
with the expression vector, encoding full-length TRAF2 (50 ng/well), and
an EV or increasing amounts of an expression vector, encoding full-length
myc-SOCS3 (see Fig. 6), using TurboFect (Thermo Scientific), according to
the manufacturer’s instructions. A total amount of 230 ng/well DNA was
kept constant by addition of the EV. After 24 h, medium was replaced, and
the cells were cultured for an additional 24 h. Thereafter, reporter gene
activity was measured using the dual-luciferase assay system (Promega, Mad-
ison, WI, USA). Data were expressed as the mean fold induction relative to
the control.
Statistical analysis
Statistical analysis was carried out using GraphPad Prism version 5.01 for
Windows (GraphPad Software, San Diego, CA, USA). Statistical analyses
were performed using the nonparametric Mann-Whitney U-test and paired
t-tests on data obtained using PBMCs and cell lines, respectively (*P0.05,
**P0.01, and ***P0.001).
RESULTS
TNF- signaling is regulated by SOCS1 and SOCS3
via a negative-feedback loop
To investigate the regulation of TNF- signal transduction, the
effect of TNF- on SOCS expression was examined in human
PBMCs. We analyzed PBMC mRNA expression of all of the
SOCS genes by RT-PCR over a time course of TNF- stimula-
tion. We found that CIS and SOCS4–7 mRNAs were constitu-
tively expressed in PBMCs and were not up-regulated in re-
sponse to TNF- (Fig. 1A). However, expression of SOCS1, -2,
and -3 mRNAs was transiently increased by TNF- (Fig. 1B).
SOCS1 and -3 protein induction mirrored the mRNA, but
SOCS2 protein was constitutively expressed and showed no
regulation by TNF- (Fig. 1C). This immediate and transient
up-regulation of SOCS1 and -3 suggests a novel role for these
inhibitory proteins in controlling TNF- signal transduction in
immune cells. SOCS are known to regulate the JAK/STAT
pathway, but only a few studies have documented their involve-
ment in NF-B signaling [16, 17, 29]. Therefore, to investigate
the effect of SOCS1 and -3 on TNF--induced NF-B activa-
tion, we treated WT, SOCS1/, SOCS3/, SOCS1, and
SOCS3 MEFs with TNF- for 0, 10, and 20 min and mea-
sured IB degradation, which occurred upon TNF- treatment
in WT, SOCS1 (SOCS1/) and SOCS3 (SOCS3/) null
cells but was inhibited in SOCS1 (SOCS1)- and SOCS3
(SOCS3)-expressing cells (Fig. 1D). SOCS1 and -3 levels
were confirmed by immunoblotting (Fig. 1E), and flow cyto-
metric analysis found surface TNFR levels to be consistent be-
tween WT, SOCS1/, SOCS3/, SOCS1, and SOCS3
MEFs (Fig. 1F). To confirm further the effect of SOCS1 and -3
on TNF--mediated IB degradation, SOCS1 and -3 constructs
were expressed in HEK293T cells before being treated with
TNF- (20 ng/ml, 20 min). Ectopic expression of SOCS1 or -3
reduced TNF--mediated IB degradation significantly com-
pared with EV control cells (Fig. 1G and H), further indicat-
ing that SOCS1 and -3 inhibit TNF--induced NF-B signaling.
Interestingly, SOCS2 did not inhibit TNF--induced IB degra-
dation (Fig. 1I).
SOCS3 is elevated, and TNF--mediated signaling is
reduced in PBMCs from HCV patients
During acute HCV infection, patients often only suffer mild,
nonspecific symptoms, demonstrating the ability of HCV to
suppress immune pathology [30]. Having observed that
SOCS1 and -3 inhibited TNF- signal transduction, we won-
dered if they were involved in suppressing its proinflammatory
effect during HCV infection. Therefore, we initially analyzed
endogenous SOCS1 and -3 mRNA levels in PBMCs from
HCV and healthy individuals. We found significantly higher
basal levels of SOCS3 mRNA in PBMCs from HCV patients,
whereas SOCS1 mRNA levels were normal when compared
with healthy controls (Fig. 2A). SOCS3 mRNA levels did not
correlate with viral load (data not shown). Having observed
elevated SOCS3 levels in HCV PBMCs, we next investigated
SOCS3 mRNA and protein regulation following TNF- stimula-
tion. Interestingly, high basal levels of SOCS3, observed at the
mRNA level, were reflected in SOCS3 protein expression (Fig.
2B and C), and SOCS3 mRNA (Fig. 2B) and protein (Fig. 2C)
were poorly induced by TNF- in HCV PBMCs compared
with healthy controls.
Having observed elevated, endogenous SOCS3 levels in PB-
MCs of HCV patients, we wondered whether this was inhibit-
ing TNF--induced NF-B signaling. Therefore, we next ana-
lyzed TNF--mediated IB degradation in PBMCs from HCV
patients. Whereas IB was degraded in PBMCs from healthy
individuals, TNF- treatment did not induce IB degradation
in PBMCs from HCV patients (Fig. 2D and E), indicating a
block in the TNF- signaling pathway. Taken together, these
results strongly suggest that HCV-induced SOCS3 expression
inhibits proinflammatory TNF- signal transduction in primary
immune cells.
TNF- proinflammatory cytokine induction is
attenuated in HCV PBMCs
As TNF- signaling was reduced in PBMCs of HCV patients,
we next investigated whether the loss in signal transduction
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affected proinflammatory cytokine induction. PBMCs from
HCV and healthy individuals were treated with TNF- for
0, 2, and 3 h, before analyzing mRNA of IL-6, TNF-, IL-8,
and CXCL-10. The mRNA level of these cytokines was up-
regulated by TNF- in PBMCs from healthy individuals.
However, while not statistically significant, IL-6 (2 h,
P0.3555; 3 h, P0.3132), IL-8 (2 h, P0.2366; 3 h,
P3.408), and TNF- (2 h, P0.2502; 3 h, P0.1658) had
Figure 1. SOCS1 and -3 mRNA and protein are regulated by TNF- in PBMCs. CIS and SOCS4–7 (A)
and SOCS1–3 (B) mRNA were analyzed by RT-PCR from PBMCs treated with TNF- (20 ng/ml) over a
time course of 0–240 min (n3; data are representative of a single sample). Protein lysates from PBMCs
treated with TNF- were analyzed by immunoblotting for SOCS1, -2, and -3 and -tubulin, using specific antibodies (C; n4). SOCS1 Null
(SOCS1/) MEFs were retrovirally infected with SOCS1 pMX-IRES-EGFP (SOCS1), and SOCS3 Null (SOCS3/) MEFs were retrovirally in-
fected with SOCS3 pMX-IRES-EGFP (SOCS3). WT, SOCS1/, SOCS1, SOCS3/, and SOCS3 MEFs were treated  TNF- (20 ng/ml, 10
and 20 min) before IB and -tubulin protein levels were quantified by immunoblotting and densitometric analysis (IB band intensity was nor-
malized to -tubulin band intensity, and all values are presented relative to unstimulated control cells, which was normalized to 1; n3; D).
SOCS1 (S1) and -3 (S3) protein levels were verified by Western blotting protein lysates using SOCS antibodies and -tubulin antibody (E). Flow
cytometric analysis of surface TNFR levels of WT, SOCS1/, SOCS1, SOCS3/, and SOCS3 MEFs stained with TNFR antibody and WT
MEFs unstained with antibody (n2; F). Protein lysates from 293T cells, transfected with myc-tagged SOCS1 and -3 constructs and treated 
TNF- (20 ng/ml, 20 min), were analyzed for IB and -tubulin by immunoblotting (n3; G). Quantification of IB expression in HEK293T
transfected with SOCS1 or -3 or EV (band intensity was normalized to -tubulin band intensity, and all values are presented relative to unstimu-
lated control cells, which were normalized to 100%; H). Immunoblot of IB expression from 293T cells transfected with myc-tagged SOCS2 or
EV constructs and treated  TNF- (20 ng/ml, 20 min) -tubulin was used as a loading control (n3; I).
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less induction in HCV PBMCs. Interestingly, after 3 h of
TNF- stimulation, CXCL-10 mRNA levels were higher in
HCV individuals (P0.4025), possibly because CXCL-10
induction is not exclusively regulated by the NF-B pathway
(Fig. 3). Overall, these findings support our hypothesis that
SOCS3-mediated inhibition of TNF- signal transduction in
HCV PBMCs may reduce the up-regulation of proinflam-
matory cytokines.
HCV-induced SOCS3 directly inhibits
TNF--mediated IL-8 production
As the inflammatory response to HCV is also mediated
through hepatocytes, we next examined the effect of HCV on
SOCS3 and TNF--induced cytokine expression in the hepato-
cyte cell line, Huh7. First, we transfected Huh7 cells with HCV
(pBRTM/HCV1-3011) or EV constructs for 24 h before analyz-
ing SOCS3 mRNA and protein. We observed a statistically sig-
Figure 2. HCV PBMCs express elevated
levels of SOCS1 and -3 and have reduced
TNF--induced IB degradation. Endoge-
nous SOCS1 (healthy, n17; HCV,
n16) and SOCS3 (healthy, n25; HCV,
n21) mRNA levels were measured in PBMCs
from healthy and HCV individuals by
real-time RT-PCR [A; mean (sem)].
PBMCs from healthy and HCV patients
were treated with TNF- (20 ng/ml) for 0,
0.5, 1, 2, and 3 h before SOCS3 mRNA was
quantified by real-time RT-PCR [healthy,
n13; HCV, n13; B; mean (sem)].
SOCS3 protein levels were analyzed by im-
munoblotting lysates of PBMCs from
healthy and HCV individuals, treated over
a time course of 0–3 h, using the appropri-
ate antibodies. Immunoblots were quanti-
fied by densitometry (band intensity was
normalized to -actin band intensity, and
all values were presented relative to un-
stimulated control cells, which were nor-
malized to 100%; n3; C). IB protein levels were measured by immunoblotting protein lysates of PBMCs from healthy (n6) and HCV (n7)
patients, treated with TNF- for 0 and 20 min (D). IB expression in HCV and healthy PBMCs was quantifed by densitometric analysis (band in-
tensity was normalized to -actin band intensity, and all values are presented relative to unstimulated control cells, which were normalized to
100%; E).
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nificant increase in SOCS3 mRNA (Fig. 4A) and enhanced
SOCS3 protein levels (Fig. 4B) upon HCV expression com-
pared with EV controls. Next, we treated these Huh7 cells with
TNF- for 18 h and measured the secreted IL-8 and CXCL-10
protein levels by ELISA. We found that IL-8 expression was
reduced significantly in Huh7 cells expressing HCV, whereas
CXCL-10 induction was not reduced (Fig. 4C). These results
indicate that as in PBMCs, HCV-induced SOCS3 expression may
reduce TNF--mediated induction of proinflammatory cytokines.
To determine the direct involvement of SOCS3 in HCV-me-
diated immune subversion, we transfected Huh7 cells with
SOCS3 shRNA or control shRNA for 24 h. After confirming
SOCS3 knockdown by qRT-PCR (Fig. 5A), we transfected
Huh7s with HCV or EV for 10 h, before stimulating with
TNF- for 18 h. We analyzed supernatants by ELISA and
found that the reduction of IL-8 in Huh7 cells expressing
HCV was restored when SOCS3 was silenced using shRNA, and
CXCL-10 levels were unaffected (Fig. 5B). Collectively, these
Figure 4. SOCS3 expression is increased, and proinflammatory cytokine IL-8 is decreased in the presence of
HCV. Huh7 cells were transfected with HCV and control EV for 24 h, followed by stimulation with TNF- (20
ng/l) for 18 h. SOCS3 mRNA (A) and protein lysates (B) were measured at time 0 by qPCR and immunoblot-
ting, respectively (n5). Mean (sd) of the relative gene expression was compared with EV. IL-8 and CXCL-10
protein were analyzed by ELISA, following 18 h stimulation with TNF-. Experiments were performed three times
in triplicate, and graphs are representative of one independent experiment (n3; C).
Figure 3. Induction of proinflam-
matory cytokines by TNF- in
healthy and HCV PBMCs. PBMCs
from healthy (n12) and HCV
(n12) individuals were treated
with TNF- (20 ng/ml) for 0, 2,
and 3 h, before IL-8, IL-6, CXCL-
10, and TNF- mRNA levels were
analyzed by real-time RT-PCR
[mean (sem)].
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results indicate that HCV-induced SOCS3 expression directly
inhibits proinflammatory TNF--mediated responses.
SOCS3 interacts with TRAF2 and inhibits
TRAF2-induced NFB promoter activation
Having found that HCV could induce SOCS3 that regulates
proinflammatory responses to TNF-, we next investigated the
mechanism by which SOCS3 inhibits TNF- signaling. To this
end, we analyzed whether there was an association between
SOCS3 and a key component of the TNF- signaling pathway,
TRAF2. We carried out immunoprecipitation assays on lysates
from HEK293T cells transfected with myc-tagged SOCS3 and
Flag-tagged TRAF2, immunoblotted for SOCS3 (myc) and
TRAF2 (Flag), and found that indeed, SOCS3 interacted with
TRAF2 (Fig. 6A). Next, with the use of a NF-B-dependent
reporter gene assay, activated by ectopic expression of TRAF2,
we investigated whether SOCS3 could inhibit activation of
NF-B signaling. We found that overexpression of SOCS3
significantly inhibited the TRAF2-dependent activation of
the NF-B reporter activity (Fig. 6B). These results are con-
sistent with HCV-induced SOCS3 as having a role in inhibit-
ing proinflammatory responses to TNF- via TRAF2 of the
NF-B pathway.
DISCUSSION
In this study, we found that TNF- transiently induced SOCS1
and SOCS3 in primary immune cells and that both proteins
Figure 5. TNF--mediated induction of IL-8 is restored when SOCS3 is silenced in HCV-infected Huh7 cells. Huh7 cells were transfected with
SOCS3 shRNA (shSOCS3) and shRNA scrambled control (shCtrl) for 24 h (n3; A). SOCS3 mRNA was analyzed by real-time RT-PCR. Relative
gene expression was compared with shRNA scrambled control (meansd). Huh7 cells were transfected with SOCS3 shRNA and shRNA for 24 h
and then transfected with HCV and EV for 10 h, before being stimulated with TNF- for 18 h (). IL-8 (n5) and CXCL-10 (n5) protein was
quantified by ELISA (B).
Figure 6. SOCS3 associates with
TRAF2 and inhibits TRAF2-medi-
ated NF-B activity. HEK293T cells
were cotransfected with myc-
tagged SOCS3 and flag-tagged
TRAF2 or EV. After 24 h, cells
were harvested and lysed, and im-
munoprecipitation (IP) of SOCS3
was performed using anti-SOCS3
antibody. Immunocomplexes were
separated by SDS gel electrophore-
sis, and immunoblotting (IB) was
performed using anti-myc and anti-
flag antibodies. Whole-cell lysates
(WCL) were also analyzed for
TRAF and SOCS3 expression using
anti-flag and anti-myc antibodies,
respectively (n3; A). HEK293T
cells were transfected with expres-
sion vectors encoding the reporter
gene NF-B and cotransfected with
EV or Flag-tagged TRAF2 (50 ng)
and increasing amounts of myc-tagged SOCS3 (10, 50, and 100 ng). Cell lysates were assessed for luciferase reporter gene activity and represented
as relative luciferase activity (RLA) to the control (n3; B).
Collins et al. HCV induces SOCS3, which regulates responses to TNF-
www.jleukbio.org Volume 96, August 2014 Journal of Leukocyte Biology 261
inhibited TNF--induced NF-B activation. Basal levels of
SOCS3 were significantly higher in PBMCs from HCV-infected
individuals, which correlated with a reduction in TNF--medi-
ated IB degradation and proinflammatory IL-6, IL-8, and
TNF- induction. Additionally, expression of HCV increased
SOCS3 expression in Huh7 cells, which directly reduced proin-
flammatory IL-8 production. We also found that SOCS3 inter-
acted with TRAF2 and blocked TRAF2-mediated NF-B re-
porter gene activation, demonstrating a potential mechanism
by which HCV-induced SOCS3 could block proinflammatory
responses to TNF-.
Whereas TNF- is critical to successful clearance of viral in-
fection, its regulation by SOCS in PBMCs has not been stud-
ied. Here, we have identified, for the first time, SOCS1 and -3
as inhibitors of TNF--induced NF-B activation, supporting
previous findings of SOCS-mediated control of TNF--regu-
lated processes, including cell death in fibroblasts and sensitiv-
ity in pancreatic  cells [31]. Indeed, SOCS1/ macrophages
produce excessive amounts of IL-12 in response to TNF-,
and TNF--induced SOCS3 generates resistance to IFN- [32],
further suggesting an important role for SOCS in the control
of TNF- signal transduction and subsequent inflammation
[33]. This study also reveals a possible mechanism by which
the association of SOCS3 with TRAF2 inhibits TRAF2-depen-
dent NF-B activation, which is reminiscent of the findings
by Frobøse et al. [34], where the interaction of SOCS3 with
TRAF6 inhibited ubiquitin modification of TRAF6 during
IL-1 signaling.
HCV has been documented to block several immune signal-
ing pathways, including the cleavage of NF-B signaling com-
ponents [35] and the proteasomal degradation of JAK-STAT
pathway components [36]; however, the effect of HCV upon
TNF--mediated inflammatory responses is poorly understood.
Our study has revealed a mechanism by which HCV-induced
SOCS3 expression may block proinflammatory TNF- signal
transduction in PBMCs. The presence of HCV in Huh7 hepa-
tocytes also significantly increased SOCS3 levels and conse-
quently, reduced proinflammatory cytokine production. This
effect was reversed when SOCS3 was silenced by shRNA, fur-
ther supporting our hypothesis that HCV-induced SOCS3 neg-
atively regulates the TNF- signaling pathway to block proin-
flammatory immune responses. Previous studies have shown
that overexpression of NS5A and NS5B inhibits TNF- signal
transduction by blocking TRADD-mediated and TRAF2- and
IB kinase-induced NF-B activation, respectively [37]. Regula-
tion of proinflammatory signals through the induction of
SOCS is an important homeostatic mechanism used to gener-
ate a controlled response to infection. Our findings suggest
that HCV-induced SOCS3 creates an environment that lacks
strong antiviral inflammation. Indeed, a prominent character-
istic of HCV infection is the prolonged nature of disease pro-
gression, often without any obvious signs of infection [38].
Our results, showing that HCV suppresses the inflammatory
response to TNF- via SOCS3 induction, might explain the
“silent” progression of acute HCV infection to chronicity, as
well as the relatively mild disease and slow progress of pathol-
ogy seen in many chronically infected HCV patients.
In conclusion, these findings suggest a novel mechanism by
which HCV-induced SOCS3 may regulate TNF- signaling and
thereby, control proinflammatory gene expression. Our results
suggest that HCV manipulates this system by inducing SOCS3
expression to suppress TNF- signaling. These discoveries may
indicate a new regulatory mechanism used by HCV to suppress
inflammation, perhaps explaining why HCV infection has lim-
ited pathology and can remain undetected for many years.
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